Disease · MONDO_0007147
obstructive sleep apnea syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. obstructive sleep apnea syndrome. Diseases, record MONDO_0007147. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007147
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Apnea, Obstructive Sleep, Apneas, Obstructive Sleep, Obstructive Sleep Apneas, Sleep Apnea Syndrome, Obstructive, Sleep Apnea, Obstructive, Sleep Apneas, Obstructive, Syndrome, Obstructive Sleep Apnea, Syndrome, Sleep Apnea, Obstructive, Syndrome, Upper Airway Resistance, Sleep Apnea, Upper Airway Resistance Sleep Apnea Syndrome, obstructive sleep apnea
- Open Targets
- Highest stage of its drugs
- Approval, for 5 of its 114 drugs, from DailyMed and EMA Human Drugs
- Open Targets
Drugs114
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PITOLISANT | CHEMBL462605 | Small molecule | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| SOLRIAMFETOL | CHEMBL4297620 | Small molecule | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| ARMODAFINIL | CHEMBL1201192 | Small molecule | Approval | DailyMed | 3 | 2 | 2 | Drugs and targets |
| MODAFINIL | CHEMBL1373 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| SOLRIAMFETOL HYDROCHLORIDE | CHEMBL4297212 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ATOMOXETINE | CHEMBL641 | Small molecule | Phase 3 | ClinicalTrials.gov | 22 | 22 | 22 | Drugs and targets |
| ESZOPICLONE | CHEMBL1522 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| AROXYBUTYNIN | CHEMBL185434 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 114
See all 114 drugsTargets173
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 8 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 7 | Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 6 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 5 | Cyclooxygenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| GABRA1 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
1 to 10 of 173
See all 173 targetsTrials159
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00228553 | Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness | Phase 3 | 743 | 2010-03-31 | Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder | ARMODAFINIL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02348632 | "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" | Phase 3 | 645 | 2019-06-25 | Narcolepsy, Obstructive Sleep Apnea | SOLRIAMFETOL | Its record names the disease | ClinicalTrials.gov |
| NCT02348606 | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" | Phase 3 | 476 | 2019-07-23 | Obstructive Sleep Apnea | SOLRIAMFETOL | Its record names the disease | ClinicalTrials.gov |
| NCT05412004 | Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Phase 3 | 469 | 2025-04-30 | Obstructive Sleep Apnea, Obesity | TIRZEPATIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02180672 | Steroids for Pediatric Apnea Research in Kids | Phase 3 | 211 | 2021-03-10 | Obstructive Sleep Apnea Syndrome | FLUTICASONE | Its record names the disease | ClinicalTrials.gov |
| NCT02348619 | "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" | Phase 3 | 174 | 2019-09-09 | Obstructive Sleep Apnea | SOLRIAMFETOL | Its record names the disease | ClinicalTrials.gov |
| NCT03471871 | Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea | Phase 1 | 146 | 2020-01-18 | Obstructive Sleep Apnea, Healthy Subjects | LEMBOREXANT | Its record names the disease | ClinicalTrials.gov |
| NCT03845023 | Trial of AD036 in Obstructive Sleep Apnea | Phase 2 | 140 | 2023-01-17 | Obstructive Sleep Apnea | ATOMOXETINE, OXYBUTYNIN | Its record names the disease | ClinicalTrials.gov |
| NCT00620659 | Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) | Phase 2 | 125 | 2011-02-23 | Sleep Apnea, Obstructive, Hypopnea Syndrome, Excessive Daytime Sleepiness | MK-0249 | Its record names the disease | ClinicalTrials.gov |
| NCT03919955 | A Novel Pharmacological Therapy for Obstructive Sleep Apnea | Phase 2 | 117 | 2025-12-23 | Sleep Apnea | ATOMOXETINE, OXYBUTYNIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 159
See all 159 trialsComparisons in its trials47
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| JZP-110 vs Placebo: deaths from any cause | 1 of 643 | 0 of 142 | 785 | NCT02348632 | Trial comparisons |
| JZP-110 vs Placebo: serious adverse events | 27 of 643 | 0 of 142 | 785 | NCT02348632 | Trial comparisons |
| JZP-110 (Entire Study) vs Placebo (Randomized Withdrawal): deaths from any cause | 0 of 174 | 0 of 62 | 236 | NCT02348619 | Trial comparisons |
| JZP-110 (Entire Study) vs Placebo (Randomized Withdrawal): serious adverse events | 0 of 174 | 0 of 62 | 236 | NCT02348619 | Trial comparisons |
| Nasal Steroids vs Placebo: deaths from any cause | 66 of 86 | 16 of 36 | 122 | NCT02180672 | Trial comparisons |
| Nasal Steroids vs Placebo: serious adverse events | 1 of 86 | 0 of 36 | 122 | NCT02180672 | Trial comparisons |
| Active Intervention vs Placebo Intervention: deaths from any cause | 0 of 55 | 0 of 55 | 110 | NCT03919955 | Trial comparisons |
| Active Intervention vs Placebo Intervention: serious adverse events | 1 of 55 | 0 of 55 | 110 | NCT03919955 | Trial comparisons |
| Inspired Oxygen vs Sham: deaths from any cause | 0 of 46 | 0 of 45 | 91 | NCT01751971 | Trial comparisons |
| Inspired Oxygen vs Sham: serious adverse events | 0 of 46 | 0 of 45 | 91 | NCT01751971 | Trial comparisons |
1 to 10 of 47
See all 47 comparisons in its trialsPapers from its trials101
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007147
GET https://conductscience.org/api/diseases/v1/MONDO_0007147/drugs?page=2